Monograph Details
|
|
Endocrine System
> Pituitary disorders
|
|
SUPPRELIN LA |
| Manufacturer |
|
Indevus Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GnRH agonist. |
| Generic Name |
|
Histrelin acetate 50mg; SC implant. |
| Indications |
|
Treatment of central precocious puberty. |
| Children |
|
<2yrs: not recommended. ≥2yrs: Insert 1 implant SC in the inner aspect of the upper arm. Remove after 12 months; may replace. Consider discontinuing at appropriate time point for onset of puberty. |
| Adults |
|
Not applicable. |
| Contraindications |
|
Pregnancy (Cat.X). |
| Precautions |
|
Use aseptic technique. Monitor LH, FSH, and estradiol or testosterone at 1 month post implantation, then every 6 months thereafter. Assess height and bone age every 6–12 months. |
| Interactions |
|
May interfere with pituitary gonadotropic and gonadal function tests. |
| Adverse Reactions |
|
Implant site reactions (eg, bruising, pain, soreness, erythema, swelling), initial worsening of signs/symptoms. |
| How Supplied |
|
Kit—1 (w. implant and insertion tool) |
|
|
|
|
